The national law firm of Parker Waichman LLP has filed 36 Fosamax lawsuits in New Jersey Superior Court, Atlantic County, against Teva Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc., and Merck Sharp & Dohme Corp. f/k/a Merck & Co alleging that long-term use of the drug has caused the plaintiffs to suffer femur fractures.
Matthew McCauley, lead attorney in the Bisphosphonate Litigation Group at Parker Waichman LLP said, “We look forward to the start of the first trials in the Fosamax litigation, tentatively scheduled for the fall. Parker Waichman LLP is hearing from women on an almost daily basis who sustained life-changing injuries similar to those suffered by our plaintiffs after using Fosamax for years.” McCauley is currently investigating Fosamax, Actonel and Boniva related femur fracture.
According to the lawsuits, the plaintiffs say they never would have used the drug if they had been properly informed of the risks associated with long-term use. The suits also allege that as a direct cause of the long-term use of Fosamax, the plaintiffs suffered and will continue to suffer severe mental and physical pain, permanent injury, emotional distress, and economic losses.
The lawsuit seeks compensatory, punitive, and treble damages, ascertainable economic losses, reimbursement of the cost of Fosamax, as well as reimbursement for all past, present, and future health and medical costs associated with use of the drug and derivative damages.